Respiratory
hiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are driven...
Neonatology
Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
Pharmacovigilance
Chiesi Group pays great attention to the safety of its products.
Following ethical principles and Russian legislation requirements, Chiesi Group collects and analyses information on adverse events, as well as maintains effective cooperation with regulatory authorities in this field.
Timely...
Mission and values
Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a collaborative...
Research and development
nnovation is the driving force behind every technologically advanced industry, but for the pharmaceutical industry it plays a vital role since it concerns the health and quality of life of people. For Chiesi, Research and Development are a true human and technological asset and, together with...
Clinical trial transparency
Running clinical trials and obtaining results is what clinical development is all about. Sharing results is very important too. Chiesi Farmaceutici S.p.A. and its affiliated companies (Chiesi) are EPFIA members, and therefore are committed to clinical trial transparency. Currently all Chiesi...
Production plants
hiesi Group has three production plants:
Parma, Italy....
Certification of working conditions
As of January 1, 2014, Federal Law No. 426-FZ of December 28, 2013, "On the Special Assessment of Working Conditions" (hereinafter Federal Law No. 426-FZ), came into force, in accordance with which, instead of certifying workplaces according to working conditions (ARM), employers are obliged to...
Ethics
Ethics is a branch of philosophy that deals with human behavior and it expresses a set of rules of conduct which should be applied in everyday actions to contribute to the common good.
Chiesi has long been in line with these general ethical principles: we want to affirm our values, build our...
Press release
Press release
Vacancies
For every employee in the Group we follow the principles of equal opportunities for everyone, mutual respect and trust along with continuous look for ways excellence. One of our key Values is people. If you wish to develop and grow professionally, if you are looking for a work in a driving team...
Work in Chiesi
Work with Us
Our culture belongs to the brave and the curious. At Chiesi we focus on finding innovative solutions and embracing new challenges. Every choice we make is driven by the will to generate a positive impact both on our community and our planet
We firmly believe that...
Pipeline
R&D Pipeline: balanced with focus
The number of research and development programmes is increasing year by year with a strong focus in three key areas: respiratory, neonatology and special care.
RESPIRATORY
Respiratory is a core area of R&D expertise, which has delivered...
AIPM Membership
Chiesi Pharmaceuticals LLS as an AIPM member company recognizes their responsibility to society. On this basis, Chiesi Pharmaceuticals LLS accepts and undertakes fulfill the requirements of the AIPM Code of Practice and to follow it not only in letter but also in spirit.
Chiesi...
Disclosure of information about the transfer of values in favor of HCP’s and HCO’s.
In accordance with the requirement of Chapter 7 "Disclosure of information about the transmission of values in favor of specialists and health care organizations" code of good practice of the Association of international pharmaceutical manufacturers (AIPM), "Chiesi Pharmaceuticals" LLC publishes on...
Annual report e brochures
-
About us
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.
Supply Chain sustainability
The UN Global Compact defines Supply Chain sustainability as “the management of environmental, social, and economic impacts, and the encouragement of good governance practices throughout the lifecycles of goods and services”.
This definition underscores the...
Credits
This project was edited and produced by Dynamic Mind.
COOKIE
WHAT ARE COOKIES?
Cookies are text files stored on your computer or mobile device when you use the Site, enabling a faster and more enjoyable online experience. You can control how cookies are used by websites by configuring the privacy settings of your browser (see your browser's help section to...
B Corp
Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It is an achievement to be proud of, and yet one that feels natural: caring for others lies at the root of health science and has always been at the...
Our approach
Sustainability has always been a primary concern in the way Chiesi operates and has increasingly become a focus with a view to shared value. Today, it represents a crucial element of the strategic vision of the company, which is committed to:
We ACT - Sustainability Manifesto
We live in a time of great change. The equilibrium of a planet exploited beyond its limits is continuously evolving. We ourselves have changed the way we live and view society. The most fragile and vulnerable pay the price: those who are often left behind in this rush to make...
Products and patients
Products and patients are two elements that are closely linked: the final result of the company’s production processes, i.e. our products, and the people who benefit from them. Our product lines are the fruit of our mission, improving the quality of life of patients, our main stakeholders....
Processes
At Chiesi, processes cover all production operations and those which enable the business to continue running, including decision-making procedures and internal company practices impacting employees and the biosphere.
We are committed to generating the following beneficial effects by means of...
Environment
The concept of health has a much broader meaning at Chiesi and also encompasses that of the planet. This is also because the health of the planet and that of its inhabitants are interdependent. We therefore aim to act as a force for good and reduce the negative impacts on the areas where we...
Our people
Chiesi employs around 6,000 people worldwide. Every day, we try to ensure an inclusive, familiar, safe and stimulating working environment for our employees, aiming to benefit from and enhance the value of cultural, gender, generational and ethnic diversity, because Every one of us is...
Corporate Citizenship
Being a good citizen is a commitment a company makes to taking economic, social, cultural and environmental responsibility for its activities in the communities where it operates. Just like any other citizen, it has rights and duties.
Inspired by the United Nations SDGs, we have created our own...
Ethics and Transparency
Guaranteeing the highest ethical standards is a daily priority for Chiesi in every aspect of its business. This means doing business on the basis of the principles of legality, fairness, integrity, responsibility and transparency.
In this regard, also in compliance with the laws and...
Communities
Chiesi’s commitment also involves promoting the development of local communities where the company operates, with the aim of facilitating sustainable growth in the area.
Sustainability at Chiesi also means recognising the strong interdependence between a company and the...
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
Chiesi Farmaceutici generated just under €1.5bn in revenue in 2015, a year-on-year increase of almost 10%.
The international footprint of the Group continues to grow: 80% of turnover is now from the non-Italian market.
The expansion of Chiesi’s US affiliate is extremely...
Chiesi certified Top Employer also for 2017
Chiesi is Top Employer Italy for the ninth consecutive year and Top Employer Europe for the fifth consecutive year, confirming to be among the entrepreneurial excellence for the working conditions of its employees. It is the independent research of the Top Employers Institute to certify it, which...
Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award
Alberto, Paolo and Andrea Chiesi are the National winners of the EY “ L’Imprenditore dell’Anno 2015” Award. The prestigious recognition, promoted by EY-Ernst & Young and sponsored by Azimut Wealth Management, is now at its 19th edition. The...
80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015
-
Europe approves Holoclar®, the first stem cell—based medicinal product
Parma/Modena (Italy), February 20, 2015 – The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea...
In Russia, a new drug for the treatment of bronchial asthma
-
Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement For a Merger Transaction
Chiesi Farmaceutici S.p.A. (“Chiesi”), a leading European pharmaceutical company, and Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (“Cornerstone”), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets,...
Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)
Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the maintenance treatment in adult patients with moderate to severe chronic obstructive...
Годовой отчет компании «Кьези» за 2019 г.: сертификат B Corp и выручка почти 2 млрд евро
-
Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH)
Press-release. Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).
CAMBRIDGE, Mass. and Parma, Italy – September 16, 2020 – Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA...
Пресс релиз. День «We Act» 2020 г.: мероприятие Группы компаний Кьези, как устойчивая инвестиция в будущее развитие
-
Группа компаний Кьези получила европейское регистрационное удостоверение на тройную комбинацию
-
Группа компаний Кьези начинает кампанию #ActionOverWords в борьбе с изменением климата
-
РЕДКИЕ ЗАБОЛЕВАНИЯ НА САМОМ ДЕЛЕ НЕ СТОЛЬ РЕДКИЕ: НАЧАЛАСЬ КАМПАНИЯ-2022 «МЫ НОСИМ ОДЕЖДУ В ПОЛОСКУ» #WEWEARSTRIPES
С новой инициативой в поддержку людей с редкими заболеваниями выступили профессиональный баскетболист Луиджи Датоме, всемирно известная теннисистка Элина...
Компания «Проталикс БиоТерапьютикс» и Глобальное подразделение по редким заболеваниям компании Кьези объявили основные результаты 24-мес
-
Российское подразделение Группы компаний «Кьези» и АО «Атомэнергопромсбыт» подписали соглашение на покупку «зеленых» сертификатов I-REC
-
Кьези проходит повторную сертификацию по стандарту B Corporation и планирует достичь новых, еще более амбициозных целей к 2025 году
-
From cells to finished product. The new Chiesi Group Biotechnology Center of Excellence opens up the future of medicine in Parma
-
Джузеппе Аккольи – новый генеральный директор группы компаний Chiesi
-
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
-
Chiesi Group mid-year financial results demonstrate strong growth for 2023
Chiesi Group announces mid-year turnover of €1,497 million;
Substantial growth of each of Chiesi’s business areas;
Europe remains the biggest market, followed by the US and China;
Forecasted revenues of about €3 billion for 2023, with an additional solid growth expected in...
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
FILSUVEZ topical gel is indicated for the treatment of partial thickness wounds in patients 6 months and older with Junctional and Dystrophic...
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
Parma, March 5th, 2024 - Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi, a fundamental pillar of the company who shaped its history alongside his brother Alberto.
Born in Parma in 1940 and graduating in Chemistry and Pharmacy, he led the Corporate Research and...
Chiesi's Global Rare Diseases Division presented results from the Phase 3 BALANCE clinical trial in patients with Fabry disease
-
Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BRIGHT Study of Pegunigalsidase Alfa in Fabry Disease
- Data published in Journal of Inherited Metabolic Disease
PARMA, October 28 , 2024 – Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced the publication of...
